

Hey everybody! Ya girl u/articzone is back for another DD on the top 5 most mentioned stocks in this sub. Below you will see the table with a few non-penny stocks that have been mentioned here, I will not be doing the DD on them.

If you're new to investing, please read the following definitions as they will be mentioned in this DD:

A **Direct public offering** (DPOs) allows a company to sell stock directly to the public without the kinks like registration and reporting requirements that an initial public offering needs. To reiterate once more, DPOs are specifically designed to let businesses access the public capital markets with less cost and complexity than is involved in IPOs.

A **stock warrant** represents the right to purchase a company's stock at a specific price and at a specific date. A stock warrant is issued directly by a company to an investor.

Share capital is the money a company raises by issuing common or preferred stock. The amount of share capital or equity financing a company has can change over time with additional public offerings

Ticker	Current mentions	Past mentions	mention % change	current price	previous close	% change	Market cap	Short Float	volume/average volume
ASRT	269	266	1.13%	1.08\$	1.05\$	2.86%	M\$184.53	2.22%	0.57
CTXR	240	873	-72.51%	2.06\$	1.56\$	32.05%	M\$154.41	4.12%	22
OBSV	107	106	0.94%	5.05\$	3.97\$	27.20%	M\$325.43	5.44%	2.1
AGTC	74	184	-59.78%	7.03\$	7.31\$	-3.83%	M\$299.89	5.10%	1.17
STX	69	71	-3%	73.14\$	72.47\$	0.93%	M\$17310.92	10.76%	0.29
ESGC	69	71	-2.82%	2.06\$	1.99\$	3.52%	M\$780.6	3.72%	0.96
CTRM	61	108	-44%	1\$	1.21\$	0%	M\$615.3	7.03%	0.49
GTE	61	108	-43.52%	0.95\$	0.93\$	2.15%	M\$344.32	0.33%	0.19
LGHL	61	108	-43.52%	5.40\$	5.91\$	-8.63%	M\$105.14	0%	3.51
AEZS	61	108	-44%	1.48\$	1.40\$	5.71%	M\$91.92	8.12%	0.18
PLTR	61	108	-43.52%	29.00\$	25.17\$	15.22%	M\$54459.97	4.17%	2.82
NAKD	35	35	0.00%	1.22\$	1.21\$	0.83%	M\$521.51	10.57%	0.63
ONTX	34	34	0%	1.64\$	1.76\$	-7.10%	M\$386.7	6.16%	0.78
GHSI	29	26	11.54%	1.09\$	1.04\$	4.81%	M\$118.42	2.66%	0.53
ADMP	25	26	-3.85%	1.38\$	1.35\$	2.22%	M\$193.59	5.47%	0.6
GSV	24	257	-90.66%	0.75\$	0.74\$	1.45%	M\$270.58	1.38%	0.64
CP	20	21	-4.76%	367.77\$	359.56\$	2.28%	M\$48739.45	0.43%	0.13
NEPT	20	21	-5%	1.96\$	1.68\$	16.67%	M\$269.83	5.56%	8.7
SOS	16	17	-6%	11.27\$	10.65\$	5.82%	M\$733.46	0%	1.53
DFFN	14	12	17%	1.32\$	1.44\$	-8.33%	M\$128.42	1.19%	0.94
TRCH	14	14	0%	3.12\$	3.24\$	-3.70%	M\$448.06	6.48%	0.51
NOVN	14	14	0.00%	2.06\$	1.90\$	8.42%	M\$291.52	4.16%	0.31
MITT	14	14	0%	4.04\$	3.43\$	17.78%	M\$164.52	4.67%	2.79

\$ASRT - Assertio is a commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers and acquisitions.

Drug pipeline:

Currently, there is 8 FDA approved drugs:

1. **ZORVOLEX®** (diclofenac) - This drug is indicated for the management of mild to moderate acute pain and the management of osteoarthritis pain. Diclofenac is a non-steroidal anti-inflammatory drug, also known as an NSAID. The lowest GoodRx price for the most common version of Zorvolex is around \$850.64.
2. **ZIPSOR®** (diclofenac potassium) - diclofenac potassium is a non-steroidal anti-inflammatory drug, also known as an NSAID. It is used to treat pain, inflammation, and swelling. The lowest GoodRx price for the most common version of Zipsor is around \$475.93.
3. **VIVLODEX®** (meloxicam) -Meloxicam is a non-steroidal anti-inflammatory drug (NSAID). It is used to reduce swelling and to treat pain, it is used for osteoarthritis. The lowest GoodRx price for the most common version of Vivlodex is around \$1,046.05.
4. **SPRIX®** (ketorolac tromethamine) - Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). It is used for a short while to treat moderate to severe pain, including pain after surgery. It should not be used for more than 5 days. The lowest GoodRx price for the most common version of generic Sprix is around \$2,217.20
5. **OXAYDO®** (oxycodone HCl, USP) - Oxycodone is a pain reliever. It is used to treat moderate to severe pain. This is a controlled substance as it's an opioid. The lowest GoodRx price for the most common version of Oxaydo is around \$1,718.68.
6. **INDOCIN®** (indomethacin) - Indomethacin is a non-steroidal anti-inflammatory drug (NSAID). It is used to reduce swelling and to treat pain. It may be used for painful joint and muscular problems such as arthritis, tendinitis, bursitis, and gout. The lowest GoodRx price for the most common version of generic Indocin is around \$15.34.
7. **INDOCIN® Oral Suspension** - Same as above

8. Cambia® (diclofenac potassium) – diclofenac potassium is a non-steroidal anti-inflammatory drug, also known as an NSAID. It treats pain, inflammation, and swelling. The lowest GoodRx price for the most common version of generic Cambia is around \$55.64.

According to their website, A next-generation Cambia is in development right now.

Recent News:

1. On Feb 5, ASRT has announced the opening of a DPO of \$14 million dollars, for a Roth Capital Partners to purchase 22,600,000 shares of its stock at a purchase price of \$0.62 per share. The DPO closed on Feb 9th.
2. On Feb 10th, the next day after the first DPO closed, a second DPO was announced of \$34.3 million dollars for Roth Capital Partners to purchase 35,000,000 shares of its common stock at a price of \$0.98 per share. It should be noted that this is a premium to market based on applicable Nasdaq “minimum price” rules. Meaning that a ticker must close above \$1 for 10 consecutive days to be listed on Nasdaq. Currently, ASRT is on day 9 of 10 of meeting compliance. Day 10 is tomorrow.
3. ASRT will release fourth quarter and full-year 2020 financial results on Thursday, March 11, 2021, after the close of markets.

Market watch rates this stock as overweight with a High of \$3.50 a Median of \$2.13 and a Low of \$0.75. The ticker currently sits at \$1.08.

1. For those that do not know what overweight means, basically, if an analyst rates a stock as “overweight,” they think that the stock will perform well in the future, and believes it is worth buying—it could outperform the broader market and other stocks in its sector.

\$CTXR – Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Product pipeline:

1. Mino-Lok® - Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients where venous access presents a challenge. In a Phase 2b trial, the Mino-Lok product demonstrated a 100% efficacy rate in salvaging colonized CVCs. FDA Fast Track with QIDP designation and patent protection until June 2024. Formulation patent protection until November 2036. Currently, they are in a phase 3 trial.
2. Halo-Lido - Halobetasol-Lidocaine Formulation (CITI-002)
 - a. Need : There are no FDA-approved prescription products on the market for hemorrhoids.
 - b. Ask : CTXR is developing a proprietary topical formulation of halobetasol and lidocaine to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.
 - c. Yes, there are many over-the-counter (OTC) products commonly used to treat hemorrhoids, just ask anyone's grandma. However, CTXR claims that none of those medications participated in a rigorously-conducted clinical trial to amplify results. Maybe that's why my grandma is still in pain. This could become the first FDA-approved product to treat hemorrhoids in the United States. Could.
3. Mino-Wrap (CITI-101) - This product is designed to reduce infections associated with the use of breast tissue expanders used in breast reconstruction surgeries following mastectomies. For all you men in this sub, a Mastectomy is performed to remove one or both breasts, partially or completely due to breast cancer mainly.
 - a. In January 2019, CTXR signed a definitive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop and commercialize this novel approach to reducing post-operative infections associated with surgical implants. Mino-Wrap is being reviewed by the FDA's Center for Drug Evaluation and Research division.

News:

1. On Feb 17, CTXR announced a DPO of \$76.5 Million to H.C. Wainwright & Co. 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of \$1.505 per share. The warrants have an exercise price of \$1.70 per share, will be immediately exercisable and will expire five years from the issue date.
2. On Feb 16, CTXR issued a shareholder letter, some highlights include:
 - a. Mino-Lok® pivotal trial interim analysis and review by the Data Monitoring Committee (DMC) expected in the second quarter
 - b. Halo-Lido IND (second quarter) and Phase 2b protocol to be filed afterwards
 - c. Mino-Wrap™ in pre-clinical development with plans to submit IND to the FDA by the end of the year
 - d. NoveCite i-MSCs development is progressing with: ongoing data generation from our proof-of-concept sheep acute respiratory distress syndrome (ARDS) model demonstrating impressive interim results (studies to be completed in second quarter); FDA-required GLP animal toxicology studies have been implemented; and development of an i-MSC master cell bank (MCB) followed by cGMP manufacturing is underway. Private placement for gross proceeds of \$20.0 million and investors' exercise of warrants generating \$4.5 million in gross proceeds completed in January 2021 and February 2021, respectively.
 - e. The walrus likes this stock.

Market watch rates CTXR as a buy with a High, Median and Low price point at \$8.00. The ticker currently sits at \$1.56.

\$OBSV – ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.

Product pipeline:

1. Linzagolix (Yselt[®]) - an orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.
2. Ebopiprant - is a potential first-in-class, novel, orally-active prostaglandin F_{2α} (PGF_{2α}) receptor antagonist designed to control preterm labor by reducing inflammation and uterine contractions as well as preventing cervical changes and fetal membrane rupture without causing the potentially serious vasoconstriction in the fetus (e.g. premature closure of the ductus arteriosus and/or renal impairment) seen with non-specific prostaglandin synthesis inhibitors such as indomethacin.
3. Nolasiban - an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This increases the chance of successful pregnancy and live-birth among patients undergoing embryo transfer following ART.

Key 2021 Objectives

1. Yselt[®] for uterine fibroids: NDA submission (Q2:21); MAA approval (Q4:21)
2. Yselt[®] for endometriosis: Phase 3 EDELWEISS 3 primary endpoint readout (Q4:21)
3. Ebopiprant for treatment of preterm labor: Phase 2b dose ranging study initiation in EU/Asia (Q4:21)

Clinical Research pipeline:

1. Primrose 1 & 2 - Are studies evaluating linzagolix in women with heavy menstrual bleeding due to uterine fibroids. Each study is treating women with either 100 mg, 200 mg of linzagolix once daily with or without add-back therapy or placebo for 24 to 52 weeks
2. Edelweiss 3 is a clinical research study evaluating linzagolix in women with endometriosis-associated pain. This study is treating women with either 75 mg of linzagolix, 200 mg of linzagolix with add-back therapy or placebo once daily for 24 weeks.

3. IMPLANT 4 is a clinical research study evaluating nolasiban in women undergoing IVF. Women receive a single administration of 900 mg of nolasiban or placebo prior to undergoing embryo transfer.
4. Prolong: Preterm labor - a clinical research study evaluating Ebopiprant (OBE022) in pregnant women with threatened spontaneous preterm labor.

News:

1. On Feb 11, OBSV announced an increase of its share capital from 69,629,347 to 81,220,471. The issue of 11,591,124 new registered shares at an issue price of 1/13 of a Swiss Franc each (remember this is a swiss company), after registration of 3,406,480 new shares issued out of the company's conditional share capital.
2. Additionally, OBSV announced it will be participating in a fireside chat and one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference on Feb 24th.

Outlook:

Market Watch rates this stock as overweight with a High of \$28.00 a Median of \$8.00 and a Low of \$4.00. Ticker closed at \$5.05

\$AGTC - At the ripe price of \$7.17 this is no longer considered a penny stock, therefore I will not update my DD. If you are interested in the DD from last week you can find it [here](#), it's a great stock.

\$ESGC - Eros STX is an entertainment and media company that creates, produces, distributes, finances and markets film, television and digital media.

1. Eros Now-
 - a. An Indian subscription online streaming platform, with a variety of tv shows and films. In January of this year, they announced a premium video-on-demand feature that releases films on the platform the same day as in theaters. Most notably is their most recent STX Films' with the hotty Gerard Butler titled "Greenland." You may have or have not seen it floating around Amazon Prime, it's a great film. Other STX Films titles that will be made available on PVID on Eros Now over the next 18 months include "Horizon Line,"

“Queenpins,” “Copshop,” “American Sole,” “The Marsh King’s Daughter,” “Run Rabbit Run,” “Devotion,” “Every Note Played,” and “Memory.” In addition to these films, ‘First Day, First Show’ will also include premium programming from multiple content partners in multiple languages.

2. STX films

- a. From blockbusters like Hustlers, Bad Moms, and The Upside to hits like The Gentlemen, Molly’s Game, and The Gift, STXfilms produced star-driven films for a global audience. In just 5 short years, its slate of films has already grossed over \$1.8b in global theatrical box office.

3. Eros STX international-

- a. is a full- service international film distribution and financing company with direct distribution of both Hollywood and Bollywood content in India, the UK, Ireland and the Middle East. Headquartered in London, the company has formalized an unrivaled network of key output deals with the major market leaders in 25 territories with a reach covering over 150 countries around the world. Embracing the unique opportunities in the international marketplace, the company recently closed an innovative and dynamic distribution output partnership with Amazon in the UK, France and Italy.

4. Eros Motion Pictures

- a. This division works mainly with their online streaming platform to develop blockbusters, like Bajirao Mastani, Bajrangi Bhaijaan, and Ram-Leela, which rank among the highest grossing Indian films of all time.

5. STX Television-

- a. Shows include Valley of the Boom for National Geographic and Rise of Empires: Ottoman for Netflix, with George Lopez’s Once Upon A Time in Aztlán in development, and a Kevin Kwan scripted series in development with a premium network.

In the news for February:

1. Daisy Ridley (Rey from Star Wars) to star in 'The Marsh King's Daughter' - STXinternational will produce and STX will distribute the film in the UK, Ireland and India.
2. Hulu on unveiled premiere dates for its spring slate of original documentaries, including a film on the "cautionary tale" of WeWork and its co-founder Adam Neumann. This will be produced by STX as well.
3. The crime thriller "Violence of Action" starring hotty Chris Pine has landed at STX films. This time the studio nabbed international rights to the movie and will also distribute it in the U.S.
4. STXtv has optioned the rights to adapt Hafsah Faizal's We Hunt the Flame, bringing the fantastical lands of the YA bestseller to television.

Market watch rates this stock as a buy with the High of \$3.50 the Median of \$3.00 and the Low of \$2.50.

\$CTRM - Castor Maritime Inc. is an international provider of shipping transportation services through its ownership of dry bulk vessels. The Company's vessels are employed primarily on short to medium term charters and transport a range of dry bulk cargoes, including such commodities as coal, grain and other materials along worldwide shipping routes. On their website, they currently feature 6 fleets, the ones below have not been updated to reflect a higher count.

In the news:

1. In January CTRM announced a \$15.3 Million Debt Financing. The loan is expected to be drawn down before the end of this month. The Company intends to use the net proceeds from the \$15.3 Million Financing to support the Company's growth plans. The \$15.3 Million Financing will have a tenor of four years from the drawdown date and will bear interest at 3.30% plus LIBOR per annum.
2. On Feb 1 CTRM purchased a 2010 Japan-built Kamsarmax dry bulk carrier from an unaffiliated third-party for a purchase price of \$15.85 million.
3. On Feb 3 CTRM purchased a 2009 Japan-built Kamsarmax dry bulk carrier from an unaffiliated third-party for a purchase price of \$14.5 million.

4. On Feb 11 CTRM agreed to purchase two 2005 Korean-built Aframax LR2 tankers from an unaffiliated third-party seller for an aggregate purchase price of \$27.2 million.
5. On Feb 18 CTRM agreed to purchase a 2010 Korean-built Kamsarmax dry bulk carrier from an unaffiliated third-party for a purchase price of \$14.8 million.

I try hard to remain as unbiased as possible, so I'd like to quickly point out that the [SEC filing shows the CEO's apartment](#). Do what you wish with this information.

Market watch does not have a rating for this stock but I did see Yahoo Finance says this stock is undervalued.

Woah another thesis completed! Thank you to everyone that has read through this all, I appreciate your feedback always. I'm currently in the process of creating a blog to house this information and to write some more, stay tuned for that announcement in hopefully a few Sundays from now.

So, what is your move for this week?
See you next Sunday!